Lucy: mitochondrial solutions to CNS diseases

Lucy Therapeutics views mitochondrial dysfunction as a common and core driver of many CNS diseases, and aims to build a pipeline of programs against “rate-limiting” targets that gate the progression of that dysfunction. First up is a program targeting F-ATPase to treat Parkinson’s disease and a second against an undisclosed GPCR for Rett syndrome.

Cambridge, Mass.-based Lucy Therapeutics Inc. has raised about $24 million across a $4 million seed round, a $15 million series A financing in December 2021, and a grant of $4.9 million from The Michael J. Fox Foundation. The company’s investors include Pivotal bioVenture Partners, Safar Partners, The Engine and the Massachusetts Life Science Center. ...